Table 2.
Volunteer ID# | Code | Serum neutralizing antibody titer on indicated day againsta:
|
|||||||
---|---|---|---|---|---|---|---|---|---|
TBEV/DEN4Δ30
|
LGT
|
||||||||
0 | 28 | 42 | 180 | 0 | 28 | 42 | 180 | ||
02 | Placebo | < 5 | < 5 | < 5 | NTb | < 5 | < 5 | < 5 | < 5 |
06 | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
12 | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
14 | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
16 | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
19 | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
25 | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
26 | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
| |||||||||
01 | Vaccine | < 5 | 14 | 9 | < 5 | < 5 | 300 | 404 | 101 |
03 | Vaccine | < 5 | < 5 | < 5 | 12 | < 5 | 10 | 20 | < 5 |
04 | Vaccine | < 5 | 23 | 8 | 33 | < 5 | 210 | 97 | 175 |
05 | Vaccine | < 5 | 318 | 164 | 186 | < 5 | 3005 | 1702 | 283 |
08 | Vaccine | < 5 | 9 | 6 | 18 | < 5 | 43 | 27 | 41 |
09 | Vaccine | < 5 | < 5 | 7 | 10 | < 5 | 35 | 25 | 11 |
10 | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 18 | 11 | 5 |
11 | Vaccine | < 5 | 11 | 8 | 25 | < 5 | 250 | 119 | 25 |
13 | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 41 | 26 | 30 |
15 | Vaccine | < 5 | < 5 | < 5 | 27 | < 5 | 54 | 64 | 65 |
17 | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | 15 |
18 | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 90 | 75 | < 5 |
20 | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 |
21 | Vaccine | < 5 | 5 | 5 | NT | < 5 | 88 | 119 | NT |
22 | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 67 | 47 | < 5 |
23 | Vaccine | < 5 | 21 | 304 | 276 | < 5 | 145 | 833 | 217 |
24 | Vaccine | < 5 | 30 | 48 | 175 | < 5 | 264 | 516 | 45 |
27 | Vaccine | < 5 | 8 | 5 | 9 | < 5 | 55 | 33 | 8 |
28 | Vaccine | < 5 | < 5 | < 5 | 6 | < 5 | < 5 | 6 | < 5 |
29 | Vaccine | < 5 | 16 | 25 | 131 | < 5 | 1252 | 850 | 191 |
| |||||||||
GMTc: | 9 | 9 | 16 | 66 | 63 | 24 | |||
|
|
||||||||
Seropositive: | 10/20 | 11/20 | 12/19 | 17/20 | 18/20 | 14/19 | |||
50% | 55% | 63% | 85% | 90% | 74% | ||||
|
|
||||||||
Seroconversion: | 4/20 | 4/20 | 7/19 | 15/20 | 16/20 | 10/19 | |||
20% | 20% | 37% | 75% | 80% | 53% | ||||
7/20 = 35% | 16/20 = 80% |
Plaque reduction (60%) neutralizing antibody titers (reciprocal) were determined against wild-type LGT TP21 strain or chimeric TBEV/DEN4Δ30 virus as indicated.
NT, not tested.
GMT, geometric mean titers (reciprocal) are calculated for all 20 vaccine recipients. For calculation of GMT, a negative titer (<1:5) was assigned a value of 4. Seroconversion (indicated by shading) is defined as a serum neutralizing antibody titer of ≥1:20 on study day 28, 42, or 180, compared with the pre-vaccination titer, which was <1:5 for each volunteer.